| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Research by Wake Forest University School of Medicine provides a crucial method for future Alzheimer's disease treatment trials and reveals key differences in how the drug is absorbed in people with early cognitive decline
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announcedthat its nasal drug delivery system was used in a recently published brain imaging study from Wake Forest University School of Medicine. According to the university's press release, the "groundbreaking" study confirms a vital step toward new Alzheimer's treatments: intranasal insulin, delivered via nasal spray, safely and effectively reaches key memory regions of the brain in older adults. The study also revealed that people with early cognitive decline may absorb it differently.
This research, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, describes the results of a milestone positron emission tomography (PET) imaging study. According to the Wake Forest team, the results directly show that intranasal insulin travels to 11 key brain regions associated with memory and cognition. Previously, researchers faced challenges in earlier intranasal insulin trials because they could not confirm if the treatment was reaching its brain targets.
The imaging protocol used a precision nasal delivery system supplied by Aptar Pharma, and could be adapted for other intranasal therapies targeting neurological disorders.
Posted In: ATR
